Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study-Reference-Cited by-同舟云学术

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

Published:2014-11 Issue:12 Volume:10 Page:3455-3465
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Einstein Mark H¹,Levin Myron J²,Chatterjee Archana³,Chakhtoura Nahida⁴,Takacs Peter⁴,Catteau Grégory⁵,Dessy Francis J⁵,Moris Philippe⁵,Lin Lan⁶,Struyf Frank⁵,Dubin Gary⁷

Affiliation:

1. Montefiore Medical Center; Albert Einstein College of Medicine; Department of Obstetrics & Gynecology and Women's Health; Bronx, NY USA

2. University of Colorado Denver and Health Sciences Center; Aurora, CO USA

3. University of South Dakota; Sanford School of Medicine and Sanford Children's Specialty Clinics; Sioux Falls, SD USA

4. University of Miami; Miami, FL USA

5. GlaxoSmithKline Vaccines; Belgium

6. XPE Pharma & Science, Wavre, Belgium, on behalf of GlaxoSmithKline Vaccines

7. GlaxoSmithKline Vaccines; King of Prussia, PA USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy